

Lars F Iversen

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8050659/publications.pdf>

Version: 2024-02-01

181
papers

7,027
citations

47006

47
h-index

79698

73
g-index

184
all docs

184
docs citations

184
times ranked

8186
citing authors

#	ARTICLE	IF	CITATIONS
1	Pregnancy outcomes in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis receiving ixekizumab. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2503-2509.	2.2	10
2	Staphylococcus aureus and Antibiotics in Cutaneous T-Cell Lymphoma. <i>Dermatology</i> , 2022, 238, 551-553.	2.1	11
3	HSP90 inhibitor RGRN305 for oral treatment of plaque-type psoriasis: efficacy, safety and biomarker results in an open-label proof-of-concept study*. <i>British Journal of Dermatology</i> , 2022, 186, 861-874.	1.5	19
4	Climatotherapy at the Dead Sea for psoriasis is a highly effective anti-inflammatory treatment in the short term: An immunohistochemical study. <i>Experimental Dermatology</i> , 2022, .	2.9	2
5	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2022, 158, 561.	4.1	12
6	Quantification of Immunohistochemically Stained Cells in Skin Biopsies. <i>Dermatopathology (Basel)</i> , 2021, 10, 107-115.	1.5	2
7	Long-term efficacy and safety of brodalumab in moderate-to-severe plaque psoriasis: a post hoc pooled analysis of AMAGINE2 and 3. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1275-1283.	2.4	8
8	Prevalence and characterization of treatment-refractory psoriasis and super-responders to biologic treatment: a nationwide study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1284-1291.	2.4	18
9	The Thioredoxin-Interacting Protein TXNIP Is a Putative Tumour Suppressor in Cutaneous T-Cell Lymphoma. <i>Dermatology</i> , 2021, 237, 283-290.	2.1	8
10	MicroRNA-93 Targets p21 and Promotes Proliferation in Mycosis Fungoides T Cells. <i>Dermatology</i> , 2021, 237, 277-282.	2.1	8
11	Diagnostic Two-Gene Classifier in Early-Stage Mycosis Fungoides: A Retrospective Multicenter Study. <i>Journal of Investigative Dermatology</i> , 2021, 141, 213-217.e5.	0.7	6
12	Spondylitis-psoriasis-enthesitis-enterocolitis-dactylitis-uveitis-peripheral synovitis (SPEED-UP) treatment. <i>Autoimmunity Reviews</i> , 2021, 20, 102731.	5.8	15
13	Anti-tumor necrosis factor agents in psoriasis: addressing key challenges using biosimilars. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 75-80.	3.1	9
14	I-Kappa-B-Zeta Regulates Interleukin-17A/Tumor Necrosis Factor-Alpha Mediated Synergistic Induction of Interleukin-19 and Interleukin-20 in Humane Keratinocytes. <i>Annals of Dermatology</i> , 2021, 33, 122.	0.9	3
15	Comorbidities in a Cohort of 66 Patients With Psoriatic Arthritis Mutilans—Results From the Nordic PAM Study. <i>Frontiers in Medicine</i> , 2021, 8, 629741.	2.6	4
16	Early efficacy and safety data with fixed-dose combination calcipotriol/betamethasone dipropionate foam attributed to mechanism of absorption and steroid potency. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 5-9.	2.4	11
17	The HSP90 inhibitor RGRN305 exhibits strong immunomodulatory effects in human keratinocytes. <i>Experimental Dermatology</i> , 2021, 30, 773-781.	2.9	15
18	Effectiveness of interdisciplinary combined dermatology-gastroenterology-rheumatology clinical care compared to usual care in patients with immune-mediated inflammatory diseases: a parallel group, non-blinded, pragmatic randomised trial. <i>BMJ Open</i> , 2021, 11, e041871.	1.9	8

#	ARTICLE	IF	CITATIONS
19	Prevalence and severity of coronary artery disease linked to prognosis in psoriasis and psoriatic arthritis patients: a multicentre cohort study. <i>Journal of Internal Medicine</i> , 2021, 290, 693-703.	6.0	23
20	Outcomes Following a Mandatory Nonmedical Switch From Adalimumab Originator to Adalimumab Biosimilars in Patients With Psoriasis. <i>JAMA Dermatology</i> , 2021, 157, 676.	4.1	24
21	Key Signaling Pathways in Psoriasis: Recent Insights from Antipsoriatic Therapeutics. <i>Psoriasis: Targets and Therapy</i> , 2021, Volume 11, 83-97.	2.2	32
22	Tissue-Resident Memory T Cells in Skin Diseases: A Systematic Review. <i>International Journal of Molecular Sciences</i> , 2021, 22, 9004.	4.1	9
23	Efficacy and safety of mogamulizumab by patient baseline blood tumour burden: a post hoc analysis of the MAVORIC trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2225-2238.	2.4	16
24	Effectiveness of brodalumab after previous treatment failure of interleukin-17A inhibitors in patients with psoriasis. <i>Dermatologic Therapy</i> , 2021, 34, e15106.	1.7	7
25	<i>Staphylococcus aureus</i> Induces Signal Transducer and Activator of Transcription 5' Dependent miR-155 Expression in Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2021, 141, 2449-2458.	0.7	15
26	IKK β is a Key Regulator of Tumour Necrosis Factor- α and Interleukin-17A-mediated Induction of Interleukin-36g in Human Keratinocytes. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00386.	1.3	5
27	Topical treatment of psoriasis: questionnaire results on topical therapy as long-term continuous treatment and use on specific body sites. <i>Journal of Dermatological Treatment</i> , 2021, 32, 916-921.	2.2	6
28	HLA-B*27 is significantly enriched in Nordic patients with psoriatic arthritis mutilans. <i>Clinical and Experimental Rheumatology</i> , 2021, 39, 775-780.	0.8	1
29	Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis: pooled analyses of two randomized phase III clinical trials (re SURFACE 1 and re SURFACE 2) through 148 weeks. <i>British Journal of Dermatology</i> , 2020, 182, 605-617.	1.5	103
30	IKK β is a key player in the antipsoriatic effects of secukinumab. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 379-390.	2.9	24
31	Systematic review of machine learning for diagnosis and prognosis in dermatology. <i>Journal of Dermatological Treatment</i> , 2020, 31, 496-510.	2.2	62
32	Deep Learning for Diagnostic Binary Classification of Multiple-Lesion Skin Diseases. <i>Frontiers in Medicine</i> , 2020, 7, 574329.	2.6	20
33	Concerns related to the coronavirus disease 2019 pandemic in adult patients with atopic dermatitis and psoriasis treated with systemic immunomodulatory therapy: a Danish questionnaire survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e773-e776.	2.4	10
34	Calcipotriol/Betamethasone Dipropionate Cutaneous Foam Treatment for Psoriasis in Patients With BSA \leq 15% and PGA \leq 3: Post-Hoc Analysis From Three Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 1111-1120.	3.0	4
35	<i>Staphylococcus aureus</i> alpha-toxin inhibits CD8 ⁺ T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma. <i>Oncolmmunology</i> , 2020, 9, 1751561.	4.6	24
36	MicroRNAs in the Pathogenesis, Diagnosis, Prognosis and Targeted Treatment of Cutaneous T-Cell Lymphomas. <i>Cancers</i> , 2020, 12, 1229.	3.7	28

#	ARTICLE	IF	CITATIONS
37	Radiographic scoring systems for psoriatic arthritis are insufficient for psoriatic arthritis mutilans: results from the Nordic PAM Study. <i>Acta Radiologica Open</i> , 2020, 9, 205846012092079.	0.6	3
38	<i>Staphylococcus aureus</i> enterotoxins induce FOXP3 in neoplastic T cells in SÅ©zary syndrome. <i>Blood Cancer Journal</i> , 2020, 10, 57.	6.2	24
39	Suppressed microRNAâ€195â€5p expression in mycosis fungoides promotes tumor cell proliferation. <i>Experimental Dermatology</i> , 2020, 30, 1141-1149.	2.9	4
40	Global reporting of cases of COVIDâ€19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. <i>British Journal of Dermatology</i> , 2020, 183, 404-406.	1.5	18
41	Effect of Dead Sea Climatotherapy on Psoriasis; A Prospective Cohort Study. <i>Frontiers in Medicine</i> , 2020, 7, 83.	2.6	13
42	<p>Dimethyl Fumarate Targets MSK1, RSK1, 2 and IKKÎ±/Î² Kinases and Regulates NF-Î±B /p65 Activation in Psoriasis: A Demonstration of the Effect on Peripheral Blood Mononuclear Cells, Drawn from Two Patients with Severe Psoriasis Before and After Treatment with Dimethyl Fumarate</p>. <i>Psoriasis: Targets and Therapy</i> , 2020, Volume 10, 1-11.	2.2	5
43	IL-37 Expression Is Downregulated in Lesional Psoriasis Skin. <i>ImmunoHorizons</i> , 2020, 4, 754-761.	1.8	18
44	Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma. <i>Blood</i> , 2019, 134, 1072-1083.	1.4	94
45	<i>Staphylococcal alpha-toxin</i> tilts the balance between malignant and non-malignant CD4⁺ T cells in cutaneous T-cell lymphoma. <i>Oncolmmunology</i> , 2019, 8, e1641387.	4.6	32
46	Localization of treatmentâ€resistant areas in patients with psoriasis on biologics. <i>British Journal of Dermatology</i> , 2019, 181, 332-337.	1.5	34
47	Review of international psoriasis guidelines for the treatment of psoriasis: recommendations for topical corticosteroid treatments. <i>Journal of Dermatological Treatment</i> , 2019, 30, 311-319.	2.2	21
48	Psoriasis and Risk of Mental Disorders in Denmark. <i>JAMA Dermatology</i> , 2019, 155, 745.	4.1	29
49	Quality of life and contact with healthcare systems among patients with psoriasis and psoriatic arthritis: results from the NORdic Patient survey of Psoriasis and Psoriatic arthritis (NORPAPP). <i>Archives of Dermatological Research</i> , 2019, 311, 351-360.	1.9	24
50	P3624Prevalence and severity of coronary artery disease linked to prognosis in psoriasis patients referred for coronary computed tomography angiography: A multicentre cohort study. <i>European Heart Journal</i> , 2019, 40, .	2.2	0
51	High-throughput RNA sequencing from paired lesional- and non-lesional skin reveals major alterations in the psoriasis circRNAome. <i>BMC Medical Genomics</i> , 2019, 12, 174.	1.5	43
52	Pemphigus Vulgaris: Short Time to Relapse in Patients Treated in a Danish Tertiary Referral Center. <i>Frontiers in Medicine</i> , 2019, 6, 259.	2.6	3
53	Clinical Goals and Barriers to Effective Psoriasis Care. <i>Dermatology and Therapy</i> , 2019, 9, 5-18.	3.0	63
54	Treatment use and satisfaction among patients with psoriasis and psoriatic arthritis: results from the NORdic Patient survey of Psoriasis and Psoriatic arthritis (NORPAPP). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 340-354.	2.4	23

#	ARTICLE	IF	CITATIONS
55	Safety of Mogamulizumab in Mycosis Fungoides and SÅ©zary Syndrome: Final Results from the Phase 3 Mavoric Study. <i>Blood</i> , 2019, 134, 5300-5300.	1.4	3
56	Non-random Plaque-site Recurrence of Psoriasis in Patients Treated with Dead Sea Climatotherapy. <i>Acta Dermato-Venereologica</i> , 2019, 99, 909-910.	1.3	9
57	Investigating the Role of I Kappa B Kinase Î¼ in the Pathogenesis of Psoriasis. <i>Acta Dermato-Venereologica</i> , 2019, 99, 1035-1036.	1.3	0
58	Letter by Hjuler et al Regarding Article, "Coronary Plaque Characterization in Psoriasis Reveals High-Risk Features That Improve After Treatment in a Prospective Observational Study" • <i>Circulation</i> , 2018, 137, 1090-1091.	1.6	0
59	Secukinumab treatment in new-onset psoriasis: aiming to understand the potential for disease modification " rationale and design of the randomized, multicenter <sc>STEP</sc>n study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1930-1939.	2.4	40
60	Risk of venous thromboembolism in patients with mycosis fungoides and parapsoriasis: A Danish nationwide population-based cohort study. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 1077-1083.e4.	1.2	5
61	Psoriasis and risk of myocardial infarction before and during an era with biological therapy: a population-based follow-up study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 2185-2190.	2.4	12
62	Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis. <i>Pharmacogenomics Journal</i> , 2018, 18, 494-500.	2.0	51
63	The effect of botulinum neurotoxin A in patients with plaque psoriasis " an exploratory trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e81-e82.	2.4	9
64	Prognostic miRNA classifier in early-stage mycosis fungoides: development and validation in a Danish nationwide study. <i>Blood</i> , 2018, 131, 759-770.	1.4	54
65	Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 3-14.	2.4	76
66	Prevalence of Psoriasis and Psoriatic Arthritis and Patient Perceptions of Severity in Sweden, Norway and Denmark: Results from the Nordic Patient Survey of Psoriasis and Psoriatic Arthritis. <i>Acta Dermato-Venereologica</i> , 2018, 99, 18-25.	1.3	16
67	Dimethyl fumarate is an allosteric covalent inhibitor of the p90 ribosomal S6 kinases. <i>Nature Communications</i> , 2018, 9, 4344.	12.8	28
68	Single-cell heterogeneity in SÅ©zary syndrome. <i>Blood Advances</i> , 2018, 2, 2115-2126.	5.2	78
69	The human <sc>IL</sc>17A/F heterodimer regulates psoriasis-associated genes through Î²BÎ¶. <i>Experimental Dermatology</i> , 2018, 27, 1048-1052.	2.9	21
70	SATB1 in Malignant T Cells. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1805-1815.	0.7	38
71	Langerhans cell markers <sc>CD</sc>1a and <sc>CD</sc>207 are the most rapidly responding genes in lesional psoriatic skin following adalimumab treatment. <i>Experimental Dermatology</i> , 2017, 26, 804-810.	2.9	11
72	Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis " nationwide results from the <sc>DERMBIO</sc> registry. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1183-1187.	2.4	21

#	ARTICLE	IF	CITATIONS
73	Reformulations of well-known active ingredients in the topical treatment of psoriasis vulgaris can improve clinical outcomes for patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1271-1284.	2.4	21
74	Immune responses and parasitological observations induced during probiotic treatment with medicinal <i>Trichuris suis ova</i> in a healthy volunteer. <i>Immunology Letters</i> , 2017, 188, 32-37.	2.5	22
75	Disease activity in and quality of life of patients with psoriatic arthritis mutilans: the Nordic PAM Study. <i>Scandinavian Journal of Rheumatology</i> , 2017, 46, 454-460.	1.1	5
76	Topical treatment of psoriasis: questionnaire results on topical therapy accessibility and influence of body surface area on usage. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 1188-1195.	2.4	16
77	Increased global arterial and subcutaneous adipose tissue inflammation in patients with moderate-to-severe psoriasis. <i>British Journal of Dermatology</i> , 2017, 176, 732-740.	1.5	41
78	TRIM21 is important in the early phase of inflammation in the imiquimod-induced psoriasis-like skin inflammation mouse model. <i>Experimental Dermatology</i> , 2017, 26, 713-720.	2.9	13
79	Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3). <i>Journal of the American Academy of Dermatology</i> , 2017, 77, 855-862.	1.2	104
80	Malignant T cells activate endothelial cells via IL-17. <i>Blood Cancer Journal</i> , 2017, 7, e586-e586.	6.2	12
81	Investigating heredity in cutaneous T-cell lymphoma in a unique cohort of Danish twins. <i>Blood Cancer Journal</i> , 2017, 7, e517-e517.	6.2	24
82	Using FDG-PET/CT to Detect Vascular Inflammation in Patients with Psoriasis: Where to Look? And for What??. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2236-2237.	0.7	2
83	Leptin deficiency in mice counteracts imiquimod (IMQ)-induced psoriasis-like skin inflammation while leptin stimulation induces inflammation in human keratinocytes. <i>Experimental Dermatology</i> , 2017, 26, 338-345.	2.9	30
84	IL-17F regulates psoriasis-associated genes through β . <i>Experimental Dermatology</i> , 2017, 26, 234-241.	2.9	24
85	Malignant inflammation in cutaneous T-cell lymphoma—a hostile takeover. <i>Seminars in Immunopathology</i> , 2017, 39, 269-282.	6.1	110
86	Methotrexate Use and Monitoring in Patients with Psoriasis: A Consensus Report Based on a Danish Expert Meeting. <i>Acta Dermato-Venereologica</i> , 2017, 97, 426-432.	1.3	41
87	Old and New Biological Therapies for Psoriasis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 2297.	4.1	179
88	STAT2 is involved in the pathogenesis of psoriasis by promoting CXCL11 and CCL5 production by keratinocytes. <i>PLoS ONE</i> , 2017, 12, e0176994.	2.5	27
89	Protein phosphatase 2C δ /Wip1 regulates phospho-p90RSK2 activity in lesional psoriatic skin. <i>Journal of Inflammation Research</i> , 2017, Volume 10, 169-180.	3.5	6
90	Association Between Changes in Coronary Artery Disease Progression and Treatment With Biologic Agents for Severe Psoriasis. <i>JAMA Dermatology</i> , 2016, 152, 1114.	4.1	75

#	ARTICLE	IF	CITATIONS
91	Comment on "Tumour necrosis factor- α plays a significant role in the Aldara-induced skin inflammation in mice": reply from authors. <i>British Journal of Dermatology</i> , 2016, 174, 1419-1420.	1.5	0
92	Identification of key research needs for topical therapy treatment of psoriasis – a consensus paper by the International Psoriasis Council. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1115-1119.	2.4	25
93	Tumour necrosis factor- α plays a significant role in the Aldara-induced skin inflammation in mice. <i>British Journal of Dermatology</i> , 2016, 174, 1011-1021.	1.5	17
94	Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a Phase 2b randomized clinical trial. <i>BMC Dermatology</i> , 2016, 16, 15.	2.1	77
95	Characterization of TNF- α and IL-17A-Mediated Synergistic Induction of β 4 Gene Expression in Human Keratinocytes through β . <i>Journal of Investigative Dermatology</i> , 2016, 136, 1608-1616.	0.7	40
96	Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma. <i>Blood</i> , 2016, 127, 1287-1296.	1.4	86
97	346 IL-17F regulates psoriasis-associated genes through β . <i>Journal of Investigative Dermatology</i> , 2016, 136, S220.	0.7	1
98	Hospital-diagnosed atopic dermatitis and long-term risk of myocardial infarction: a population-based follow-up study. <i>BMJ Open</i> , 2016, 6, e011870.	1.9	24
99	Patient Preferences for Topical Psoriasis Treatments are Diverse and Difficult to Predict. <i>Dermatology and Therapy</i> , 2016, 6, 273-285.	3.0	23
100	Interleukin 20 regulates dendritic cell migration and expression of co-stimulatory molecules. <i>Molecular and Cellular Therapies</i> , 2016, 4, 1.	0.2	19
101	The role of leptin in psoriasis comprises a proinflammatory response by the dermal fibroblast. <i>British Journal of Dermatology</i> , 2016, 174, 187-190.	1.5	15
102	Patient-relevant needs and treatment goals in nail psoriasis. <i>Quality of Life Research</i> , 2016, 25, 1179-1188.	3.1	16
103	Pathway Analysis of Skin from Psoriasis Patients after Adalimumab Treatment Reveals New Early Events in the Anti-Inflammatory Mechanism of Anti-TNF- α . <i>PLoS ONE</i> , 2016, 11, e0167437.	2.5	11
104	STAT5 induces miR-21 expression in cutaneous T cell lymphoma. <i>Oncotarget</i> , 2016, 7, 45730-45744.	1.8	45
105	Radiographic development during three decades in a patient with psoriatic arthritis mutilans. <i>Acta Radiologica Open</i> , 2015, 4, 205846011558809.	0.6	3
106	Comparative Analysis of Two Gene-Targeting Approaches Challenges the Tumor-Suppressive Role of the Protein Kinase MK5/PRAK. <i>PLoS ONE</i> , 2015, 10, e0136138.	2.5	15
107	Changes in β mRNA expression precede changes in micro RNA expression in lesional psoriatic skin during treatment with adalimumab. <i>British Journal of Dermatology</i> , 2015, 173, 436-447.	1.5	34
108	Tofacitinib withdrawal and retreatment in moderate-to-severe chronic plaque psoriasis: a randomized controlled trial. <i>British Journal of Dermatology</i> , 2015, 172, 1395-1406.	1.5	127

#	ARTICLE	IF	CITATIONS
109	Low-Dose (10-Gy) Total Skin Electron Beam Therapy for Cutaneous T-Cell Lymphoma: An Open Clinical Study and Pooled Data Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 138-143.	0.8	64
110	Increased Prevalence of Coronary Artery Disease in Severe Psoriasis and Severe Atopic Dermatitis. <i>American Journal of Medicine</i> , 2015, 128, 1325-1334.e2.	1.5	94
111	IL-17 is a key driver in the development of psoriasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, E5825-33.	7.1	95
112	Comparison of long-term drug survival and safety of biologic agents in patients with psoriasis vulgaris. <i>British Journal of Dermatology</i> , 2015, 172, 244-252.	1.5	239
113	Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1128-1134.	2.4	164
114	Aldara-induced skin inflammation: studies of patients with psoriasis. <i>British Journal of Dermatology</i> , 2015, 172, 345-353.	1.5	42
115	Jak3, STAT3, and STAT5 inhibit expression of miR-22, a novel tumor suppressor microRNA, in cutaneous T-Cell lymphoma. <i>Oncotarget</i> , 2015, 6, 20555-20569.	1.8	78
116	Inflammatory Cytokines Break Down Intrinsic Immunological Tolerance of Human Primary Keratinocytes to Cytosolic DNA. <i>Journal of Immunology</i> , 2014, 192, 2395-2404.	0.8	44
117	Efficacy of ustekinumab in palmoplantar pustulosis and palmoplantar pustular psoriasis. <i>International Journal of Dermatology</i> , 2014, 53, e464-6.	1.0	31
118	Interleukin 20 protein localizes to distinct mononuclear cells in psoriatic skin. <i>Experimental Dermatology</i> , 2014, 23, 349-351.	2.9	11
119	Subsequent cancers, mortality, and causes of death in patients with mycosis fungoides and parapsoriasis: A Danish nationwide, population-based cohort study. <i>Journal of the American Academy of Dermatology</i> , 2014, 71, 529-535.	1.2	24
120	Staphylococcal enterotoxins stimulate lymphoma-associated immune dysregulation. <i>Blood</i> , 2014, 124, 761-770.	1.4	59
121	MicroRNA expression in early mycosis fungoides is distinctly different from atopic dermatitis and advanced cutaneous T-cell lymphoma. <i>Anticancer Research</i> , 2014, 34, 7207-17.	1.1	55
122	Anti-inflammatory effect of a retrovirus-derived immunosuppressive peptide in mouse models. <i>BMC Immunology</i> , 2013, 14, 51.	2.2	5
123	The expression of dual-specificity phosphatase 1 mRNA is downregulated in lesional psoriatic skin. <i>British Journal of Dermatology</i> , 2013, 168, 339-345.	1.5	15
124	STAT1 expression and activation is increased in lesional psoriatic skin. <i>British Journal of Dermatology</i> , 2013, 168, 302-310.	1.5	78
125	Studies of JAK/STAT3 expression and signalling in psoriasis identifies STAT3 ser727 phosphorylation as a modulator of transcriptional activity. <i>Experimental Dermatology</i> , 2013, 22, 323-328.	2.9	86
126	MicroRNA normalization candidates for quantitative reverse-transcriptase polymerase chain reaction in real time in lesional and nonlesional psoriatic skin. <i>British Journal of Dermatology</i> , 2013, 169, 677-681.	1.5	7

#	ARTICLE	IF	CITATIONS
127	Bacterial Toxins Fuel Disease Progression in Cutaneous T-Cell Lymphoma. <i>Toxins</i> , 2013, 5, 1402-1421.	3.4	66
128	IL-20, IL-21 and p40: Potential Biomarkers of Treatment Response for Ustekinumab. <i>Acta Dermato-Venereologica</i> , 2013, 93, 150-155.	1.3	29
129	<sc>TNF</sc> and <sc>IL</sc>-17A-mediated S100<sc>A</sc>8 expression is regulated by p38 <sc>MAPK</sc>. <i>Experimental Dermatology</i> , 2013, 22, 476-481.	2.9	34
130	Mice Lacking MSK1 and MSK2 Show Reduced Skin Tumor Development in a Two-Stage Chemical Carcinogenesis Model. <i>Cancer Investigation</i> , 2011, 29, 240-245.	1.3	30
131	CCL27 expression is regulated by both p38 MAPK and IKK ² signalling pathways. <i>Cytokine</i> , 2011, 56, 699-707.	3.2	12
132	The role of mitogen- and stress-activated protein kinase 1 and 2 in chronic skin inflammation in mice. <i>Experimental Dermatology</i> , 2011, 20, 140-145.	2.9	19
133	Kinetics and differential expression of the skin-related chemokines CCL27 and CCL17 in psoriasis, atopic dermatitis and allergic contact dermatitis. <i>Experimental Dermatology</i> , 2011, 20, 789-794.	2.9	58
134	Dimethylfumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (S63) and p-p53 (S15) expression. <i>Inflammation Research</i> , 2011, 60, 643-653.	4.0	35
135	Tumor Necrosis Factor α -Mediated Induction of Interleukin 17C in Human Keratinocytes Is Controlled by Nuclear Factor κ B. <i>Journal of Biological Chemistry</i> , 2011, 286, 25487-25494.	3.4	51
136	Role of p38 Mitogen-activated Protein Kinase Isoforms in Murine Skin Inflammation Induced by 12-O-tetradecanoylphorbol 13-acetate. <i>Acta Dermato-Venereologica</i> , 2011, 91, 271-278.	1.3	12
137	Caspase-5 Expression Is Upregulated in Lesional Psoriatic Skin. <i>Journal of Investigative Dermatology</i> , 2011, 131, 670-676.	0.7	61
138	Adalimumab therapy rapidly inhibits p38 mitogen-activated protein kinase activity in lesional psoriatic skin preceding clinical improvement. <i>British Journal of Dermatology</i> , 2010, 162, 1216-1223.	1.5	31
139	Preferential inhibition of the mRNA expression of p38 mitogen-activated protein kinase regulated cytokines in psoriatic skin by anti-TNF α therapy. <i>British Journal of Dermatology</i> , 2010, 163, 1194-1204.	1.5	57
140	A characterization of the expression of 14-3-3 isoforms in psoriasis, basal cell carcinoma, atopic dermatitis and contact dermatitis. <i>Dermatology Reports</i> , 2010, 2, 14.	0.8	8
141	The p38 MAPK Regulates IL-24 Expression by Stabilization of the 3' UTR of IL-24 mRNA. <i>PLoS ONE</i> , 2010, 5, e8671.	2.5	35
142	MK2 regulates the early stages of skin tumor promotion. <i>Carcinogenesis</i> , 2009, 30, 2100-2108.	2.8	35
143	Characterization of the interleukin-17 isoforms and receptors in lesional psoriatic skin. <i>British Journal of Dermatology</i> , 2009, 160, 319-324.	1.5	303
144	The expression and phosphorylation of eukaryotic initiation factor 4E are increased in lesional psoriatic skin. <i>British Journal of Dermatology</i> , 2009, 161, 1059-1066.	1.5	16

#	ARTICLE	IF	CITATIONS
145	The caspase-cleaved form of LYN mediates a psoriasis-like inflammatory syndrome in mice. <i>EMBO Journal</i> , 2009, 28, 2449-2460.	7.8	17
146	Reduced Oxazolone-Induced Skin Inflammation in MAPKAP Kinase 2 Knockout Mice. <i>Journal of Investigative Dermatology</i> , 2009, 129, 891-898.	0.7	36
147	IL-8 and p53 are inversely regulated through JNK, p38 and NF- κ B p65 in HepG2 cells during an inflammatory response. <i>Inflammation Research</i> , 2008, 57, 329-339.	4.0	30
148	Pro-inflammatory cytokine release in keratinocytes is mediated through the MAPK signaling-integrating kinases. <i>Experimental Dermatology</i> , 2008, 17, 498-504.	2.9	38
149	The kinases MSK1 and MSK2 act as negative regulators of Toll-like receptor signaling. <i>Nature Immunology</i> , 2008, 9, 1028-1036.	14.5	297
150	The expression of IL-20 and IL-24 and their shared receptors are increased in rheumatoid arthritis and spondyloarthritis. <i>Cytokine</i> , 2008, 41, 16-23.	3.2	98
151	Inflammasomes and inflammatory caspases in skin inflammation. <i>Expert Review of Molecular Diagnostics</i> , 2008, 8, 697-705.	3.1	30
152	IL-20 Gene Expression Is Induced by IL-1 β through Mitogen-Activated Protein Kinase and NF- κ B-Dependent Mechanisms. <i>Journal of Investigative Dermatology</i> , 2007, 127, 1326-1336.	0.7	52
153	Mitogen- and Stress-Activated Protein Kinase 2 and Cyclic AMP Response Element Binding Protein are Activated in Lesional Psoriatic Epidermis. <i>Journal of Investigative Dermatology</i> , 2007, 127, 2012-2019.	0.7	34
154	Dimethylfumarate Specifically Inhibits the Mitogen and Stress-Activated Kinases 1 and 2 (MSK1/2): Possible Role for its Anti-Psoriatic Effect. <i>Journal of Investigative Dermatology</i> , 2007, 127, 2129-2137.	0.7	57
155	The Activity of Caspase-1 Is Increased in Lesional Psoriatic Epidermis. <i>Journal of Investigative Dermatology</i> , 2007, 127, 2857-2864.	0.7	80
156	Mitogen- and Stress-Activated Protein Kinase 1 Is Activated in Lesional Psoriatic Epidermis and Regulates the Expression of Pro-Inflammatory Cytokines. <i>Journal of Investigative Dermatology</i> , 2006, 126, 1784-1791.	0.7	58
157	Protein Expression of TNF- α in Psoriatic Skin Is Regulated at a Posttranscriptional Level by MAPK-Activated Protein Kinase 2. <i>Journal of Immunology</i> , 2006, 176, 1431-1438.	0.8	130
158	The mitogen-activated protein kinases p38 and ERK1/2 are increased in lesional psoriatic skin. <i>British Journal of Dermatology</i> , 2005, 152, 37-42.	1.5	177
159	The dynamics of gene expression of interleukin-19 and interleukin-20 and their receptors in psoriasis. <i>British Journal of Dermatology</i> , 2005, 153, 911-918.	1.5	101
160	Inverse Regulation of the Nuclear Factor- κ B Binding to the p53 and Interleukin-8 κ B Response Elements in Lesional Psoriatic Skin. <i>Journal of Investigative Dermatology</i> , 2005, 124, 1284-1292.	0.7	53
161	Tumor necrosis factor- α -induced CTACK/CCL27 (cutaneous T-cell-attracting chemokine) production in keratinocytes is controlled by nuclear factor κ B. <i>Cytokine</i> , 2005, 29, 49-55.	3.2	57
162	Signal transduction pathways in human epidermis. <i>European Journal of Dermatology</i> , 2005, 15, 4-12.	0.6	40

#	ARTICLE	IF	CITATIONS
163	Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin. <i>British Journal of Dermatology</i> , 2004, 151, 600-607.	1.5	32
164	1 α ,25(OH)2D3 regulates NF- κ B DNA binding activity in cultured normal human keratinocytes through an increase in I κ B α expression. <i>Archives of Dermatological Research</i> , 2004, 296, 195-202.	1.9	66
165	Growth medium-dependent ERK1/2 and AP-1 activity in cultured normal human keratinocytes modulates 1 α ,25-dihydroxyvitamin D3-induced differentiation. <i>Archives of Dermatological Research</i> , 2003, 295, 199-202.	1.9	0
166	1 α ,25-Dihydroxyvitamin D3 Stimulates Activator Protein 1 DNA-Binding Activity by a Phosphatidylinositol 3-Kinase/Ras/MEK/Extracellular Signal Regulated Kinase 1/2 and c-Jun N-Terminal Kinase 1-Dependent Increase in c-Fos, Fra1, and c-Jun Expression in Human Keratinocytes. <i>Journal of Investigative Dermatology</i> , 2003, 120, 561-570.	0.7	55
167	Expression and Localization of Peroxisome Proliferator-Activated Receptors and Nuclear Factor κ B in Normal and Lesional Psoriatic Skin. <i>Journal of Investigative Dermatology</i> , 2003, 121, 1104-1117.	0.7	105
168	Modulation of Keratinocyte Gene Expression and Differentiation by PPAR-Selective Ligands and Tetradecylthioacetic Acid. <i>Journal of Investigative Dermatology</i> , 2001, 116, 702-712.	0.7	213
169	1 α ,25-Dihydroxyvitamin D3 Induced Differentiation of Cultured Human Keratinocytes is Accompanied by a PKC-Independent Regulation of AP-1 DNA Binding Activity. <i>Journal of Investigative Dermatology</i> , 2000, 114, 1174-1179.	0.7	38
170	Upregulation of Nuclear PKC and MAP-Kinase During Hyperproliferation of Guinea Pig Epidermis: Modulation by 13-(S)-Hydroxyoctadecadienoic Acid (13-HODE). <i>Cellular Signalling</i> , 1998, 10, 143-149.	3.6	17
171	The role of leukotriene A4 hydrolase/aminopeptidase in transcellular leukotriene B4 synthesis in human epidermis. <i>Acta Dermato-venereologica Supplementum</i> , 1997, 199, 1-28.	0.0	1
172	LTA4 hydrolase in human skin: decreased activity, but normal concentration in lesional psoriatic skin. <i>Archives of Dermatological Research</i> , 1996, 288, 217-224.	1.9	10
173	Cyclosporin A down-regulates the LTA4 hydrolase level in human keratinocyte cultures. <i>Acta Dermato-Venereologica</i> , 1996, 76, 424-428.	1.3	2
174	Incorporation of 15-hydroxyeicosatrienoic acid in specific phospholipids of cultured human keratinocytes and psoriatic plaques. <i>Experimental Dermatology</i> , 1995, 4, 74-78.	2.9	11
175	Purification and characterization of leukotriene A4hydrolase from human epidermis. <i>FEBS Letters</i> , 1995, 358, 316-322.	2.8	17
176	Human epidermis transforms exogenous leukotriene A4 into peptide leukotrienes: possible role in transcellular metabolism. <i>Archives of Dermatological Research</i> , 1994, 286, 261-267.	1.9	32
177	Distribution of monohydroxy fatty acids in specific human epidermal phospholipids. <i>Experimental Dermatology</i> , 1993, 2, 38-44.	2.9	10
178	Effect of dihomogammalinolenic acid and its 15-lipoxygenase metabolite on eicosanoid metabolism by human mononuclear leukocytes in vitro: selective inhibition of the 5-lipoxygenase pathway. <i>Archives of Dermatological Research</i> , 1992, 284, 222-226.	1.9	41
179	Linoleic acid and dihomogammalinolenic acid inhibit leukotriene B4 formation and stimulate the formation of their 15-lipoxygenase products by human neutrophils in vitro. Evidence of formation of antiinflammatory compounds. <i>Agents and Actions</i> , 1991, 33, 286-291.	0.7	57
180	Circulating Brodalumab Levels and Therapy Outcomes in Patients With Psoriasis Treated With Brodalumab. <i>JAMA Dermatology</i> , 0, , .	4.1	5

#	ARTICLE	IF	CITATIONS
181	Comorbidity in Adult Psoriasis: Considerations for the Clinician. Psoriasis: Targets and Therapy, 0, Volume 12, 139-150.	2.2	10